Jefferies analyst Chris Howerton maintains Provention Bio (NASDAQ:PRVB) with a Buy and raises the price target from $18 to $22.
FDA Accelerated Approval Of Tofersen Highlights Importance Of Blood Neurofilament Light Chain As Surrogate Endpoint In Neurology Therapeutic Trials
Blood-based measurement of neurofilament light chain (NfL) provides compelling evidence to support an accelerated drug approval by the FDA. The decision has positive implications for NfL blood testing as a key tool in
